Send to

Choose Destination
Genes Chromosomes Cancer. 2016 Oct;55(10):741-9. doi: 10.1002/gcc.22381. Epub 2016 Jul 7.

Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis.

Author information

Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
ARC-NET Research Center, University and Hospital Trust of Verona, Verona, Italy.
Department of Pathology, Santa Chiara Hospital, Trento, Italy.
Department of Medicine (DIMED), University of Padua, Padua, Italy.
Institute of Clinical Research and Education in Medicine, Padua, Italy.
Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN.
Health Service and Population Research Department, King's College London, De Crespigny Park, London, UK.
Department of Neuroscience, University of Padua, Padua, Italy.
Department of Surgery, University and Hospital Trust of Verona, Verona, Italy.
Department of Pathology, the Johns Hopkins University, Baltimore, MD.


Biallelic inactivation of the tumor suppressor gene BRCA1-associated protein 1 (BAP1) has been demonstrated in several cancers, but its prognostic role has not been completely explained. We aimed to investigate the risk associated with loss of BAP1 (BAP1-) for all-cause mortality, cancer-specific mortality and recurrence of disease in subjects with cancer. PubMed and SCOPUS were searched from database inception until 09/15/2015 without language restrictions. Prospective studies reporting data on prognostic parameters in subjects with cancer, comparing participants with presence of BAP1 (BAP1+) vs. BAP1- were included. Data were summarized using risk ratios (RR) for number of deaths/recurrences and hazard ratios (HR) for time-dependent risk related to BAP1- adjusted for potential confounders. From 261 hits, 12 studies (including 13 cohorts) with 3,447 participants (BAP1-: n = 697; BAP1+: n = 2,750), with a median follow-up over 60 months, were meta-analyzed. Compared to BAP1+, BAP1- significantly increased all-cause mortality, cancer-specific mortality and risk of recurrence in all the tumor types analyzed, except for mesothelioma, in which the presence of BAP1 mutations correlates with a better prognosis. Furthermore, we demonstrated that BAP1 mutated colorectal and renal carcinomas are associated with high-tumor grading (P < 0.0001), and that BAP1 mutated is more common in women than in men (P < 0.0001). In conclusion, on the basis of our meta-analysis, we have demonstrated a peculiar role of BAP1 in influencing the prognosis in cancer. Thus, BAP1 could be considered as an important potential target for personalized medicine.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center